Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia

Suttorp M, Sembill S, Metzler M (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Klinische Pädiatrie Georg Thieme Verlag

DOI: 10.1055/a-1248-2294

Abstract

Background CML comprises only 2-3 % of all diagnosed pediatric leukemias. Mostly diagnosed in chronic phase (CML-CP), the disease progresses without treatment to accelerated phase (CML-AP) and finally to life-limiting blastic phase (CML-BP). Contrasting the therapy of other leukemia types, CML-CP is not treated by intense chemotherapy but with oral drugs - termed tyrosine kinase inhibitors (TKI)- for an unlimited duration. This therapy may be associated with general and developmental-specific side effects. The rarity of pediatric-CML is limiting the experience in assessment of the disability rating (DR) as an administrative health authority procedure.

Authors with CRIS profile

Markus Metzler Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie

Involved external institutions

Technische Universität Dresden DE Germany (DE)

How to cite

APA:

Suttorp, M., Sembill, S., & Metzler, M. (2020). Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia. Klinische Pädiatrie. https://doi.org/10.1055/a-1248-2294

MLA:

Suttorp, Meinolf, Stephanie Sembill, and Markus Metzler. "Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia." Klinische Pädiatrie (2020).

BibTeX: Download